Drug intelligence / Profile preview

SG404

Development stage: Preclinical
Lead developer: Somagenics
Modality: Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics

Overview

SG404 is a short hairpin RNA (sshRNA) therapeutic candidate developed by SomaGenics. It is part of SomaGenics' sshRNA platform, which utilizes RNA interference (RNAi) technology. The drug is being investigated for its potential to treat chronic diabetic wounds. SomaGenics is advancing its preclinical wound healing program for SG404 through a research collaboration with LayerBio and Dr. Geoffrey Gurtner's lab at Stanford University School of Medicine. The development of SG404 for accelerating wound healing is supported by a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

Targets

EGLN1 (Prolyl hydroxylase domain-containing protein 2)

Beyond the preview

Go deeper on SG404.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SG404.

Explore the full profile